Literature DB >> 33785648

Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation.

Weini Wang1, Fang Fang1, Ali Ozes1, Kenneth P Nephew2,3.   

Abstract

Ovarian cancer is a chemoresponsive tumor with very high initial response rates to standard therapy consisting of platinum/paclitaxel. However, most women eventually develop recurrence, which rapidly evolves into chemoresistant disease. Persistence of ovarian cancer stem cells (OCSCs) at the end of therapy has been shown to contribute to resistant tumors. In this study, we demonstrate that the long noncoding RNA HOTAIR is overexpressed in HGSOC cell lines. Furthermore, HOTAIR expression was upregulated in OCSCs compared with non-CSC, ectopic overexpression of HOTAIR enriched the ALDH+ cell population and HOTAIR overexpression increased spheroid formation and colony-forming ability. Targeting HOTAIR using peptide nucleic acid-PNA3, which acts by disrupting the interaction between HOTAIR and EZH2, in combination with a DNMT inhibitor inhibited OCSC spheroid formation and decreased the percentage of ALDH+ cells. Disrupting HOTAIR-EZH2 with PNA3 in combination with the DNMTi on the ability of OCSCs to initiate tumors in vivo as xenografts was examined. HGSOC OVCAR3 cells were treated with PNA3 in vitro and then implanted in nude mice. Tumor growth, initiation, and stem cell frequency were inhibited. Collectively, these results demonstrate that blocking HOTAIR-EZH2 interaction combined with inhibiting DNA methylation is a potential approach to eradicate OCSCs and block disease recurrence. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33785648      PMCID: PMC8172444          DOI: 10.1158/1535-7163.MCT-20-0826

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  51 in total

Review 1.  The snail superfamily of zinc-finger transcription factors.

Authors:  M Angela Nieto
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

2.  A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy.

Authors:  Xingang Li; Hongming Lu; Guilian Fan; Miao He; Yu Sun; Kai Xu; Fengjun Shi
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-20       Impact factor: 4.553

3.  Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.

Authors:  Jason R Brown; Daniel K Chan; Jessica J Shank; Kent A Griffith; Huihui Fan; Robert Szulawski; Kun Yang; R Kevin Reynolds; Carolyn Johnston; Karen McLean; Shitanshu Uppal; J Rebecca Liu; Lourdes Cabrera; Sarah E Taylor; Brian C Orr; Francesmary Modugno; Pooja Mehta; Michael Bregenzer; Geeta Mehta; Hui Shen; Lan G Coffman; Ronald J Buckanovich
Journal:  JCI Insight       Date:  2020-06-04

4.  The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Authors:  Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

5.  NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.

Authors:  Timothy Nacarelli; Takeshi Fukumoto; Joseph A Zundell; Nail Fatkhutdinov; Stephanie Jean; Mark G Cadungog; Mark E Borowsky; Rugang Zhang
Journal:  Cancer Res       Date:  2019-12-19       Impact factor: 12.701

6.  HOX transcript antisense RNA (HOTAIR) in cancer.

Authors:  Xiaohan Qu; Simon Alsager; Ying Zhuo; Bin Shan
Journal:  Cancer Lett       Date:  2019-04-12       Impact factor: 8.679

7.  DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.

Authors:  A Ahluwalia; J A Hurteau; R M Bigsby; K P Nephew
Journal:  Gynecol Oncol       Date:  2001-08       Impact factor: 5.482

8.  Epigenetic resensitization to platinum in ovarian cancer.

Authors:  Daniela Matei; Fang Fang; Changyu Shen; Jeanne Schilder; Alesha Arnold; Yan Zeng; William A Berry; Tim Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2012-05-01       Impact factor: 12.701

9.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.

Authors:  L Hu; C McArthur; R B Jaffe
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

10.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more
  3 in total

Review 1.  Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.

Authors:  Jacek R Wilczyński; Miłosz Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

Review 2.  Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance.

Authors:  Chunming Zhu; Xia Wang; Yuan Wang; Kefeng Wang
Journal:  Cell Death Discov       Date:  2022-09-13

3.  Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).

Authors:  Chen Lyu; Lili Wang; Birgit Stadlbauer; Elfriede Noessner; Alexander Buchner; Heike Pohla
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.